COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,225 Articles (22,733 medRxiv, 8,492 bioRxiv)

Most recent first Previous |  Page 71: Articles 701-710  | Next

Kozak sequence libraries for characterizing transgenes across expression levels
Shukla, N., Kamath, N. D., Snell, J. C., Bruchez, A. M., Matreyek, K. A.
10.1101/2025.04.28.651141 — Posted: 2025-04-30
MAVS Orchestrates a Potent IFN-independent Antiviral Immunity by Preserving Mitochondrial Integrity
Sah, V., Potharaju, P. S., Nair, K. S., Sahoo, P. P., Pooja, A. R., Basu, D., Tandel, D., Varadarajan, K. S., Chauhan, S., Patel, A. B., Harshan, K. H.
10.1101/2025.04.28.651145 — Posted: 2025-04-30
Long-COVID Postural Tachycardia Syndrome: A deep phenotyping study
Larsen, N. W., Machnik, J. V., Seliger, J., Shaik, R., Gibbons, C. H., Utz, P. J., Lansberg, M. G., Muppidi, S., Jaradeh, S., Miglis, M. G.
10.1101/2025.04.28.25326587 — Posted: 2025-04-29
Prevalence of Long COVID in Mycobacterium tuberculosis-Exposed Groups in Peru and Kenya
Ongaya, A., Cardenas Jara, A. R., Likhovole, C. R., Ramos, L. B., Senador, L., Flores, J. A., Kanoi, B., Reijneveld, J. F., Ruvalcaba, A., Perez, D., Waiganjo, P., Lindestam Arlehamn, C. S., Henrich, T. J., Peluso, M. J., Leon, S. R., Gitaka, J., Suliman, S.
10.1101/2025.04.28.25326537 — Posted: 2025-04-29
Frequency, Dynamics, and Duration of Fecal Shedding in SARS-CoV-2 Infected Individuals, a Scoping Review
Buchholz, U., Abunijela, S., Greiner, T., Haas, W., Schattschneider, A., Puetz, P., Kerber, R., Schumacher, J.
10.1101/2025.04.29.25326628 — Posted: 2025-04-29
Return to Work with Long COVID: A Rapid Review of Support and Challenges
Daniels, S., Wei, H., McElvenny, D. M., van Tongeren, M., Bramwell, D., Coleman, A., Forde, D., Wiggans, R.
10.1101/2025.04.29.25326647 — Posted: 2025-04-29
Robust and Reliable de novo Protein Design: A Flow-Matching-Based Protein Generative Model Achieves Remarkably High Success Rates
Yan, J., Cui, Z., Yan, W., Chen, Y., Pu, M., Li, S., Ye, S.
10.1101/2025.04.29.651154 — Posted: 2025-04-29
mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 variant in the lower and upper respiratory tract
Hazell, N. C., Reyna, R. A., Bonam, S. R., Bei, J., Kumar, N., Nguyen, T. N., Plante, J. A., Walker, D. H., Wang, T., Plante, K. S., Hu, H.
10.1101/2025.04.28.650951 — Posted: 2025-04-29
Highly potent antiviral drug candidates targeting SARS-CoV-2 nsp3 and nsp5
Galais, M., HERLEM, G., HAIDAR AHMAD, S., Pasquereau, S., EL BABA, R., BELLEFROID, M., PLANT, E., MOROT-BIZOT, S., PICAUD, F., HERBEIN, G., Van Lint, C. M.
10.1101/2025.04.28.650947 — Posted: 2025-04-29
Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida
Levi, R., Mansuri, F., Jordan, M., Ladapo, J.
10.1101/2025.04.25.25326460 — Posted: 2025-04-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).